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The aim of this study was to check the relationship between the density of urinary EVs, their size distribution, and the progress
of early renal damage in type 2 diabetic patients (DMt2). Patients were enrolled to this study, and glycated hemoglobin (HbA1c)
below 7% was a threshold for properly controlled diabetic patients (CD) and poorly controlled diabetic patients (UD). Patients
were further divided into two groups: diabetic patients without renal failure (NRF) and with renal failure (RF) according to
the Glomerular Filtration Rate. Density and diameter of EVs were determined by Tunable Resistive Pulse Sensing. Additionally,
EVs were visualized by means of Transmission and Environmental Scanning Electron Microscopy. Nano-liquid chromatography
coupled offline with mass spectrometry (MALDI-TOF-MS/MS) was applied for proteomic analysis. RF had reduced density of
EVs compared to NRF. The size distribution study showed that CD had larger EVs (mode) than UD (115 versus 109 nm; 𝑝 < 0.05);
nevertheless themeanEVsdiameterwas smaller in controls than in theCDgroup (123 versus 134 nm;𝑝 < 0.05). It was demonstrated
that EVs are abundant in urine. Albumin, uromodulin, and number of unique proteins related to cell stress and secretion were
detected in the EVs fraction. Density and size of urinary EVs reflect deteriorated renal function and can be considered as potential
renal damage biomarkers.
1. Introduction
Recently, the incidence of diabetes mellitus has grown signif-
icantly throughout the world and diabetes becomes the most
common cause of kidney injury. It is supposed that about
30 percent of patients with diabetes of type 1 (DMt1) and 10
to 40 percent of those with type 2 (DMt2) will suffer from
renal damage [1–3]. Most of cells release small membrane
spherical structures called extracellular vesicles (EVs) which
can be classified into three groups: exosomes (50–100 nm),
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microvesicles (100–1000 nm), and apoptotic bodies. These
vesicles differ in their composition and subcellular origin.
EVs can be found in several body fluids, including plasma,
urine, saliva, and milk [4]. In particular, urine is a rich
reservoir of these vesicles which originate from the cells
facing the urinary lumen (epithelial cells). The urinary EVs
can reflect the state of the damage of the kidney. Results
of several studies indicate that EVs originating from urine
have recently emerged as an interesting source of diagnostic
disease biomarkers and contain molecules involved in inter-
cellular communication [5–9]. Changes in excretion rates of
specific proteins also can have predictive value in the early
diagnosis of renal damage [10].
Existing clinical markers such as serum creatinine or
urine albumin level are not very sensitive and are generally
increased when acute or chronic renal injury is well estab-
lished [11]. Reliable biomarkers of renal injury are lacking in
the renal care. Creatinine measured by laboratories provides
little information about the underlying cause of renal injuries
and is less accurate for patients with lowmuscle mass [12, 13].
In diabetes, the most serious and life treating complication
is diabetic nephropathy. To avoid this end stage complica-
tion there is a growing need to discover novel noninvasive
biomarkers of primary renal damage which allow detecting
changes in kidney at early stage [14]. In the present study we
test the hypothesis that the density and size of urinary EVs
can be considered as biomarkers of renal damage in DMt2
patients.
The motivation of this study was to demonstrate the
potential usefulness of urinary EVs in diagnostics of early
renal failure as a complication of diabetes. In order to achieve
this goal we applied the modern approach for urine analysis:
Tunable Resistive Pulse Sensing (TRPS) for EVs enumeration
and size distribution analysis, a nano-liquid chromatog-
raphy technique coupled offline with mass spectrometry
(MALDI-TOF-MS/MS) for proteomic analysis and elec-
tronmicroscopy (Transmission ElectronMicroscopy (TEM);
Environmental Scanning Electron Microscopy (ESEM)) for
EVs visualization.
2. Materials and Methods
2.1. Study Group. Sixty patients (20 women and 40 men)
with type 2 diabetes mellitus (DMt2) were enrolled to the
present study. These patients were divided into groups: CD,
properly controlled (𝑛 = 24), and UD, poorly controlled
diabetes (𝑛 = 36). As a control, ten healthy subjects (4 women
and 6 men) with an average age of 52 (SD = 7) years were
included. The studied groups were allocated according to the
criterion of glycated hemoglobin (HbA1c) levels. According
to Polish Diabetes Association guidelines from 2014, a HbA1c
level of 7% is general criterion of carbohydrate metabolism
compensation. Patients in whom HbA1c levels exceed 7%
are considered as they have poorly controlled diabetes. What
is more, diabetic patients were further classified into two
groups: diabetic patientswithout renal failure (NRF) andwith
renal failure (RF). A selection of RF was Glomerular Fil-
tration Rate (GFR) below 60mL/min/1.73m2 from MDRD2
formula. Microalbuminuria was defined as 20–200mg/L and
macroalbuminuria>200mg/L albuminfiltration.The clinical
characteristics of the studied groups are presented in Tables 1
and 2.
2.2. Urine Samples Collection and Preparation. First morning
urine specimens were collected into sterile containers (F.L.
Medical SRL, Torreglia, Italy) from diabetic patients and
healthy subjects. Typically 50mL first void urine was used
for the isolation of the urinary extracellular vesicles and pro-
cessed within 2 h of collection. Samples were centrifuged in
a Hermle Z300K (Hermle Labortechnik GmbH, Wehingem,
Germany) for 10min in 3000g at 4∘C to remove cells and
larger debris. After this step supernatants were aliquoted and
frozen at −80∘C for further analysis. Immediately before the
TRPS measurement, samples were thawed in a water bath
at 37∘C and then vortexed for 30 s, diluted 1 : 1 in PBS (Cat.
number P4417, Sigma-Aldrich, St. Louis, USA), vortexed for
10 s, and used for analysis. For mass spectrometry and elec-
tronmicroscopy analysis, supernatants were ultracentrifuged
in 150 000g for 1 h at 4∘C (Optima MAX-XP, Beckman
Coulter Life Sciences, Indianapolis, USA) using a horizontal
rotor (Cat. number 367280, MLS-50 Swinging-Bucked Rotor,
Beckman Coulter Life Sciences, Indianapolis, USA).
2.3. Blood Samples. Blood samples for biochemical and
hematology analysis were drawn by venipuncture of the
antecubital vein using a 21-gauge needle and the Sarst-
edt S-Monovette blood collection system (Sarstedt AG &
Co., Nu¨mbrecht, Germany) following application of a light
tourniquet. For complete blood count analysis and HbA1c
levels, EDTA anticoagulant was used. For biochemical analy-
sis, blood was collected in serum separator tubes. Standard
blood tests were performed by means of the hematology
analyzer (ELITech Group, Puteaux, France). HbA1c level was
measured onD-10 analyzer (D-10 hemoglobin testing system,
Bio-Rad Laboratories Inc., California, USA).
2.4. Tunable Resistive Pulse Sensing Technology. The size and
density of urinary EVs were determined by Tunable Resistive
Pulse Sensing (TRPS) technique using qNano system and
tunable pore specimen, NP150 from Izon Science (Izon
Science Ltd., Christchurch, New Zealand). Principles of the
technique were described in [15–18]. To detect particles in
the range 60–480 nm the pores labeled NP150 were used.
Polystyrene beads of known raw concentration (1.5𝐸 +
13/mL) and diameter of 105 nm were sourced from Izon
Science and were used as a calibrant. Typically a bandwidth
filter of 5 kHzwas applied duringmeasurements. For the elec-
trolyte and dilution buffer we used PBS. In all measurements
75 𝜇L of electrolyte buffer was placed in the lower fluid cell
and the volume in the upper fluid cell was 40 𝜇L. Each sample
was measured in triplicate. The density, mean, and mode
diameter of EVs are expressed as median (IQR). Data capture
was performed using Izon’s control suite 3.1 software.
2.5. Proteomics (Nano-LC-MALDI-TOF/TOFMass Spectrom-
etry). For proteomics analysis urinary EVs were isolated
from microalbuminuric (CD) and macroalbuminuric (UD)
patients and healthy subjects, at least 𝑛 = 3 from each
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Table 1: Clinical characteristics, blood, and urine biochemistry of study groups: C, CD, and UD.
C
𝑛 = 10
CD
𝑛 = 24
UD
𝑛 = 36
𝑝 value
Age
(years) 52 (7) 62 (15)
† 61 (12)† 0.0683
Gender
(male/female) 6/4 17/7 23/13 —
Serum glucose 5.2 6.8†∗ 9†∗
<0.0001
(mmol/L) (5.0–5.5) (5.9–7.9) (7.4–12)
Urine albumin 6 6∗ 37†∗
<0.0001
(mg/L) (4–13) (2–22) (12–267)
Urine creatinine 15 5† 7† 0.0054
(mmol/L) (9–17) (4–9) (5–11)
Serum creatinine
(𝜇mol/L)
72
(60–85)
77
(67–98)
79
(62–108) 0.4696
GFR
(mL/min/1.73 m2)
87
(76–101)
77
(59–95)
79
(59–97) 0.5114
EVs density 5.2𝐸10 8.4𝐸10 5.2𝐸10 0.5013
(number/mL) (2.7𝐸10–1.9𝐸11) (3.9𝐸10–1.7𝐸11) (2.6𝐸10–1.5𝐸11)
EVs mode diameter 106 115†∗ 109∗ 0.0212
(nm) (104–110) (107–118) (106–112)
EVs mean diameter
(nm) 123 (4) 134 (11)
† 129 (8) 0.0065
†Significant in comparison with the control group at 𝑝 < 0.05.
∗Significant difference between subgroups CD and UD at 𝑝 < 0.05.
Bold means statistically significant difference between the three groups at 𝑝 < 0.05.
Table 2: Clinical characteristics, blood, and urine biochemistry of study groups: C, RF, and NRF.
C
𝑛 = 10
RF
𝑁 = 15
NRF
𝑁 = 45
𝑝 value
Age
(years) 52 (7) 69 (11)
†∗ 60 (3)†∗ 0.0027
Gender
(male/female) 6/4 15/3 25/17 —
Serum glucose 5.2 8.7† 7.9†
<0.0001
(mmol/L) (5.0–5.5) (6.5–11) (6.5–10)
Urine albumin 6† 51† 14 0.0923
(mg/L) (4–13) (7–359) (4–58)
Urine creatinine 15 6† 8† 0.0046
(mmol/L) (9–17) (5–8) (4–11)
Serum creatinine 72 119†∗ 73∗
<0.0001
(𝜇mol/L) (60–85) (111–123) (60–84)
GFR 87 49†∗ 89∗
<0.0001
(mL/min/1.73m2) (76–101) (39–55) (73–105)
EVs density 5.2𝐸10 2.6𝐸10∗ 8.7E10∗ 0.0361
(number/mL) (2.7𝐸10–1.9𝐸11) (2.0𝐸10–8.2𝐸10) (4.0𝐸10–1.9𝐸11)
EVs mode diameter
(nm)
106
(104–110)
111
(105–115)
109
(107–115) 0.1965
EVs mean diameter 122 129 129† 0.0101
(nm) (120–126) (123–138) (126–136)
†Significant in comparison with the control group at 𝑝 < 0.05.
∗Significant difference between subgroups RF and NRF at 𝑝 < 0.05.
Bold means statistically significant difference between the three groups at 𝑝 < 0.05.
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group. After ultracentrifugation, urine supernatants (6mL)
were used for analysis. Obtained pellet was resuspended
in 60 𝜇L 10% SDS (Cat. number L3771, Sigma-Aldrich, St.
Louis, USA), 10 𝜇L 1M TRIS (Cat. number T1503 Sigma-
Aldrich, St. Louis, USA), and 30 𝜇L deionized water [19].
Protein concentration was determined using BCA method
(Cat. number 23227, Pierce Biotechnology,Thermo Scientific,
USA). Mean protein concentration was 1.14 ± 1.04mg/mL;
the total protein amount used for MS was 40 𝜇g. Proteomic
analysis was performed by means of a nano-liquid chro-
matograph (EASY-nLC II, Bruker Daltonics, Germany).
The detailed methodology was previously published [20].
The precision tolerance was 100 ppm for peptide masses and
0.7Da for fragment ion masses. Individual peptide matches
with scores above 28 were considered statistically significant.
Proteins identification was performed manually, based on
two unique peptides with the probability less than 0.05.
The protein classification was performed by means of a free
algorithm applied in the PANTHER Classification System
(Version 11.0, released July 15, 2016) [21]. The analysis of
overlapping proteins within healthy subjects, CD, and UD
was performed by a tree-circle Venn diagram software [22].
2.6. Transmission Electron Microscopy and Environmental
Scanning Electron Microscopy
2.6.1. ESEM. Urine sample from a healthy donor (100mL)
was centrifuged in 3000g and next supernatant was ultracen-
trifuged in 150 000g for 1 h at 4∘C. EVs pellet was resuspended
in 60 𝜇L of PBS and 20𝜇L of EVs solution was placed on
1 × 1 cm poly-l-lysine slide (Cat. number J2800 AMNZ,
ThermoFisher Scientific,Waltham,Massachusetts, USA) and
incubated for 1 h in humid chamber at RT. After incuba-
tion the slide was washed twice in PBS and fixed in 3.7%
glutaraldehyde in PBS for 30min followed by salt removal
stage. The slide with EVs was washed with two aqueous PBS
dilutions, 50% PBS, 25% PBS, and deionized water, each for
1 minute. Next, the dehydration was applied by immersing
sample for 30 seconds in ethyl alcohol solutions as follows:
10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, and absolute
ethanol. Afterwards, sample was dried for 24 h under cover at
RT [23].
The Environmental Scanning Electron Microscopy
(ESEM) measurements were performed using SEM Quanta
3D FEG microscope by FEI Company (USA) operated
at Institute of Physics Jagiellonian University, Krako´w,
Poland. The ESEM images were collected by GSED detector
using electrons of 5 keV energy. During measurements the
specimen was kept at 100 Pa of water vapor at RT.
2.6.2. TEM. Two urine samples from a healthy donor and
one UDwere prepared in the same way as for ESEM analysis.
Samples were centrifuged in Eppendorf tube and fixed with
2.5% glutaraldehyde (Cat. number G5882, Sigma-Aldrich, St.
Louis, USA) in 0.1M cacodylic buffer (Cat. number C4945,
Aldrich, St. Louis, USA) for 2 h at RT and then postfixed in 1%
osmium tetroxide solution (1 hour). Sampleswere dehydrated
by passing through a graded ethanol series and embedded in
PolyBed 812 at 68∘C.
Ultrathin sections were collected on 300 mesh grids
or one slot made from copper. Additionally the latter was
covered with formvar film. Next the sections were contrasted
using uranyl acetate and lead citrate. For observation the
electronmicroscopy from JEOL company JEOL JEM 2100HT
(Jeol Ltd, Tokyo, Japan) was used at accelerating voltage
80 kV.
2.7. CD81 TRIFIc Exosome Assay. Europium Time Resolved
Fluorescence assay, Cat. number EX103 (Cell Guidance
Systems Ltd., Cambridge, United Kingdom), was used to
measure abundance of human CD81 protein in the surface
of exosomes in the same urine samples. In the TRIFIc
exosome assay the same antibody is used for binding of
target to the assay plate and for detection. This assay consists
of a monoclonal antibody (labeled with biotin) bound to
streptavidin coated plate that captures proteins which are
present in the surface of exosomes. An identical monoclonal
antibody (labeled with Europium) is used for detection.
Europium provides a high degree of sensitivity for the assay.
For fluorescence detection we used infinite M200 PRO plate
reader (Tecan Group Ltd., Ma¨nnedorf, Switzerland).
2.8. Statistical Analysis. Statistica 12 (Dell Statistica,
Tulsa, USA) and OriginPro 2016 (OriginLab Corporation,
Northampton, USA) were used for statistical analyses and
plots design.The distribution of continuous data was verified
with Shapiro-Wilk normality test. Results are expressed as
mean (SD) for data with normal distribution or median
and interquartile ranges (Q1–Q3) for data with not normal
distribution. Biochemical and epidemiological data were
analyzed by one-way analysis of variance ANOVA or
Kruskal-Wallis for comparison among groups. Differences
between subgroups were tested with Tukey’s post hoc test or
Dunn’s multiple comparison test. The Mann–Whitney U test
was used to compare differences between two independent
groups. Correlations between EVs density and biochemical
parameters were calculated with Spearman’s rank correlation
test, and multiple regression (backward stepwise regression)
was performed to predict the effect of age on the other
variables. For all analyses 𝑝 values < 0.05 were considered
significant.
2.9. Ethical Considerations. This study was approved by The
Bioethical Committee of Jagiellonian University in Krako´w
on 24 October 2013 which accepted all project’s protocols
and forms, including an information for patients form and
a consent form.The permission number KBET/206/B/2013 is
valid until 31 December 2016.
3. Results
A comparison of biochemical parameters such as serum glu-
cose, urine albumin, urine creatinine, serum creatinine, GFR,
EVs density, EVs mode, and mean diameter in CD, UD, and
the control groupwas provided inTable 1. Properly controlled
diabetic patients (CD) and poorly controlled diabetic patients
(UD) had significantly higher levels of serum glucose (6.8
versus 5.2mmol/L; 𝑝 < 0.0001 and 9 versus 5.2mmol/L; 𝑝 <
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Table 3: Results of Spearman’s rho test for correlations between EVs density and biochemical parameters.
C
𝑛 = 10
CD
𝑛 = 24
UD
𝑛 = 36
RF
𝑛 = 15
NRF
𝑛 = 45
Serum glucose 0.49 −0.27 −0.33 −0.66 −0.21
(mmol/L) 𝑝 = 0.15 𝑝 = 0.19 𝑝 = 0.05 p = 0.01 𝑝 = 0.16
Urine creatinine 0.08 0.52 0.03 −0.46 0.33
(mmol/L) 𝑝 = 0.83 p = 0.01 𝑝 = 0.87 𝑝 = 0.08 p = 0.03
Urine albumin −0.16 0.37 0.14 −0.03 0.25
(mg/L) 𝑝 = 0.65 𝑝 = 0.08 𝑝 = 0.42 𝑝 = 0.92 𝑝 = 0.09
GFR 0.50 0.26 0.27 −0.54 0.07
(mL/min/1.73m2) 𝑝 = 0.14 𝑝 = 0.21 𝑝 = 0.12 p = 0.04 𝑝 = 0.66
Bold means statistically significant correlation at 𝑝 < 0.05 level.
0.0001) and lower urine creatinine concentration (5 versus
12mmol/L; 𝑝 = 0.003 and 7 versus 12mmol/L; 𝑝 = 0.004)
in comparison with the control group.
Our results showed statistically significant difference in
serum glucose (6.8 versus 9mmol/L; 𝑝 = 0.0001) and
urine albumin (6 versus 37mg/L; 𝑝 = 0.002) between
CD and UD groups. No significant difference was found
in serum creatinine concentration, GFR and EVs density
between these groups. Size distribution analysis showed that
CD had significantly larger EVs mode diameter besides UD
(115 versus 109 nm; 𝑝 = 0.031). The mean EVs diameter was
smaller in controls than in the CD group (123 versus 134 nm;
𝑝 = 0.004).
A comparison of biochemical parameters in RF, NRF, and
the control group is provided in Table 2. Compared with the
control group, RF had significantly higher levels of serum
glucose (8.7 versus 5.2mmol/L; 𝑝 < 0.0001) and serum
creatinine (119 versus 72 𝜇mol/L; 𝑝 < 0.0001) and lower
urine creatinine concentration (6 versus 15mmol/L; 𝑝 =
0.002) and GFR (49 versus 87mL/min/1.73m2; 𝑝 < 0.0001).
NRF had significantly higher levels of serum glucose (7.9
versus 5.2mmol/L; 𝑝 < 0.0001) and lower urine creatinine
concentration (8 versus 15mmol/L;𝑝 = 0.003) in comparison
with the healthy subjects.
The obtained results indicate that RF had significantly
reduced density of EVs compared to NRF (2.57E10 versus
8.73E10 number/mL; 𝑝 = 0.017). We observed statistically
significant difference in serum creatinine (119 versus 73
𝜇mol/L; 𝑝 < 0.0001) and GFR (49 versus 89mL/min/1.73m2;
𝑝 < 0.0001) between RF and NRF groups and in albumin
level between RF and healthy subjects (51 versus 6.2mg/L;
𝑝 = 0.02). Because of high variability within patients
groups, no significant difference was found between EVs
mode diameters between RF and NRF.
Results of Spearman’s rho test for relationship between
EVs density and biochemical parameters are presented in
Table 3. We observed a negative tendency between EVs den-
sity and serum glucose level in UD (R = −0.33) and negative
correlation in RF (R = −0.66) patients (Figure 2). There was
no correlation between these parameters in CD (𝑝 = 0.19)
and NRF (𝑝 = 0.16). We found positive relationship between
EVs density and urine creatinine concentration in CD (R =
0.52) and NRF (R = 0.33) (Figure 3).There was no correlation
between these parameters in UD (𝑝 = 0.87) and RF (𝑝 =
0.08).
Taking into consideration that the age can influence
renal function, multiple regression (backward stepwise
regression) was performed to show the impact of age
on changes in the amount of EVs (see Supplementary
Table 1 in the Supplementary Material available online
at http://dx.doi.org/10.1155/2016/5741518). Additionally, the
correlations of specific biochemical parameters (creatinine,
albumin, serum glucose, etc.) with age have been analyzed.
Not surprisingly, there was no correlation in control group.
The age related negative relationship was observed in CD
and NRF group in terms of creatinine clearance (GFR).
Such relationship was less significant in patients with more
advanced stage of disease (Supplementary Table 2).
Environmental Scanning Electron Microscopy (ESEM)
confirmed the presence of the EVs in pellets sedimented after
ultracentrifugation of collected samples (Figures 1(a)–1(d)).
Washed EVs formed clustered aggregates, which were better
distinguishable by means of TEM (Figures 1(e) and 1(f)).
The size of EVs was estimated in the range of 130–160 nm.
However, a number of smaller and bigger vesicles and other
objects were observed.
In order to see the origin and biological activity of
analyzed EVs, the proteomic analysis of a urinary EVs
fraction was performed. Despite the fact that urine samples
were obtained from patients in different stage of DM and
different albuminuria levels, the albumin was the main and
most abundant protein detected using mass spectrometry
methods (Figures 4(a) and 4(b)). The second abundant
protein in urine was uromodulin. Venn analysis shows the
possible relationships in a protein profile between CD and
UD compared to a control subject. Among total 92 proteins
in CD, 49 were unique and 31 were common in CD and
UD (Supplementary Table 1). In the UD sample, the total
number of proteins was 45 while in the control sample 17
proteins were found. The list of unique proteins for every
group was listed in Supplementary Table2. For prediction of
common protein interactions the list of common 45 proteins
was analyzed by means of Search Tool for the Retrieval
of Interacting Genes/Proteins (STRING) [24] (Figure 4(b)).
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(a) (b)
(c) (d)
(e) (f)
Figure 1: Environmental Scanning Electron Microscopy (ESEM) (a–d) and Transmission Electron Microscopy (e, f) images of urinary
extracellular vesicles (EVs) isolated from a urine sample. ESEM images show that EVs form aggregates and they are clustered on the surface.
TEM analysis visualizes the variety of different vesicle-like objects in diameter mostly around 130–160 nm. Interestingly, multivesicle objects
were also present in urine that confirms integrity of EVs during preparation.
This analysis revealed the central role of albumin in EVs
fraction, nevertheless stress related proteins (ceruloplasmin,
transferrin) and cellular components (mostly exosome and
extracellular region) (Figures 4(c) and 4(d)).
CD81 TRIFIc exosome assay has not shown any statistical
significant differences in CD81 level between study groups,
what is presented in Figure 5.
4. Discussion
To date, there are no noninvasive methods to characterize
renal structural pathophysiological changes [25]. Moreover,
biochemical markers are not sensitive enough to characterize
the risk of progression of nephropathy and other DM-related
complications [13].
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Figure 2: Relationship between EVs density and serum glucose level in study groups: CD (a), UD (b), NRF (c), and RF (d). EVs density
values are given as mean (SD). Spearman’s rank correlation coefficient, 𝑝 < 0.05.
In this study we sought to test if the density and size
of urinary EVs can be considered as potential biomarkers
of early renal damage in DMt2 patients which can lead to
diabetic nephropathy. Additionally, we studied if there is any
correlation between EVs density and biochemical parameters
in diabetic patients and healthy control group.
Our results indicate that diabetic patients with renal
failure (RF) had lower density of EVs compared to diabetic
patients without renal failure (NRF). The size distribution
study showed significant difference in EVs mode diameter
between CD and UD. Turco et al. [26] showed that decreases
of EVs may reflect atherosclerosis and thrombosis-related
activity in renal capillaries and parenchyma.
Currently kidney function is monitored by measur-
ing serum creatinine, creatinine clearance, and proteinuria.
These clinical markers are usually a late sign of renal damage
and indicate its dysfunction [6]. What is more, these markers
do not always correlate well with the severity of renal damage
seen on biopsy [27]. The early stages of renal functions
impairment are diagnosed only bymeasuring GFR.The com-
plications of chronic renal disease increase with decreasing
GFR [28].There are a number of studies confirming the huge
impact of GFR level in progression of renal damage [29–
32]. However, a good biomarker of decreased GFR, together
with a proper marker of tubular injury, would allow for the
diagnosis of renal failure in diabetic patients before increased
albuminuria and irreversible kidney damage [13].
One of the specific renal proteins—uromodulin—has
been found as urinary biomarker which positively correlates
with GFR ratio and decreased uromodulin concentrations
have been found in renal failure and diabetic nephropathy
[33, 34]. In our study, we observed that uromodulin is a
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Figure 3: Relationship between EVs density and urine creatinine concentration in study groups: CD (a), UD (b), NRF (c), and RF (d). EVs
density values are given as mean (SD). Spearman’s rank correlation coefficient, 𝑝 < 0.05.
prominent protein related to EVs and we may assume that
its drop in urine concentrations is related to decreased EV
density in patient with renal failure. Uromodulin is probably
involved in EVs clustering and precipitation (Figure 1(c))
[35].
In our study, we observed a negative correlation between
EVs density and serum glucose level in RF and a negative ten-
dency between these parameters in UD. Mehta [36] showed
that the kidney is intimately involved in the development
of hyperglycemia in the critically ill patients. Sechi et al.
[37] demonstrated that abnormal plasma glucose levels were
elevated when the GFR was <50mL/min/1.73m2 and overall
glucose metabolism parameters were not correlated with
microalbuminuria (MA). These data are consistent with our
study. We did not observe the correlation between MA and
the EVs density in both CD and UD, as well as in RF
and NRF. Thus we may assume that EVs presence is more
related with impaired glucose metabolism and then with
the presence of renal damage biomarker (MA) and EVs can
be treated as the more ominous label of disease in diabetic
patients. Interestingly, we also observed a positive correlation
between EVs density and urine creatinine concentration in
NRF and CD, in contrast to those with more advanced
disease stage (RF) or impropriate treatment (UD). This
observation may suggest that the early renal dysfunction
processes are more considerable in the urine EVs release. In
the milder stage of renal failure we may expect the higher
number of EVs in urine, as the primary marker of the renal
dysfunction. In further study the more specific attention
should be focused on the correlation between cystatin C
and even angiopoietin 2, which appeared to be a relevant
predictor of renal dysfunction in acute pancreatitis patients
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Figure 4: Proteomic analysis of urinary extracellular vesicles: mass spectrometry results from representative samples. (a) Venn diagram
shows that in EVs from controlled diabetic patient with microalbuminuria there is a large number of unique proteins (𝑛 = 49), in a healthy
control and in an uncontrolled diabetic patient with macroalbuminuria the number of unique proteins is very low (𝑛 = 4) [20]. (b) Protein-
to-protein interaction analysis of common 45 proteins selected from Venn diagram shows the central role of albumin among urinary EV-
related proteins; the list of submitted proteins is available in a supplementary data file (Supplementary Table 2) [22]. (c, d) Gene Ontology
analysis showed that most of identified proteins are related to extracellular region or they are related to membrane organelles (exosomes);
their localization corresponds with molecular function (receptors and transport proteins) [19]. A1BG: alpha-1-B glycoprotein; A2M:
alpha-2-macroglobulin; ACTB: actin, beta; AFM: afamin; ALB: albumin; AMBP: alpha-1-microglobulin/bikunin precursor; ANPEP: alanyl
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Figure 5: Urine CD81 level. Results from Time Resolved Fluores-
cence assay. Kruskal-Wallis test: median TRF counts, 𝑝 = 0.5 at 𝛼 <
0.05 significance level.
[38]. Age is the strongest factor influencing physiological
state, as well as renal function. According to the number
of epidemiological studies, GFR declines with age average
about 0.8mL/min/1.73m2 per year. The multiple regression
(backward stepwise regression) model did not show the
significant impact of age on changes in the amount of EVs.
Urinary EVs are enriched in membrane and cytosolic
cargo proteins from the different epithelial cells lining the
urinary track. To date, there are only few studies to reveal the
new urine biomarkers, which are based on proteomic meth-
ods. Among them, proteases and protease inhibitors includ-
ing kallikreins [6, 10, 14] and metalloproteinases (MMP-2,
MMP-7, andMMP-8) have been observed in normoalbumin-
uria and microalbuminuria groups. In macroalbuminuric
patients, cathepsin D has been more abundant than in
other patients [14]. In our study we found new protease
inhibitors including inter-alpha-trypsin inhibitor (AMBP-
Human), inhibitor of the complement membrane attack
complex (CD59) and proteases including mannan-binding
lectin serine protease 2 (MASP2 Human). A large number
of unique proteins in controlled diabetes can be used in
selection of potential biomarkers in further studies on the risk
of diabetic nephropathy in such patients.
According to our observations the specific marker for
exosomes (CD81) did not show significant difference in the
level (Figure 5).TheCD81 is a surface exosomemarker which
belongs to the tetraspanin family (TAPA-1) and is involved
in signal transduction and cell adhesion [39]. CD81 protein
is enriched in the exosome membrane [40]. However, it has
not been shown if this biomolecule distinguish the severity
of renal disease in diabetic patients. We may also speculate
that in our study we did not observe significant differences in
CD81 level between groups because the most numerous was
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CD81-negative (nonexosomes) population of microvesicles,
membrane bubbles above 100 nm (Figures 1(e) and 1(f)).
In our study we confirmed that the quantitative analysis
of urinary EVs seems to be a promising tool for defining
new biomarkers [41]. We pictured that EVs are present in
urine and they maintain their integrity during sampling
and preparation process. However, most of these studies are
focused on the two areas of progress: bladder or prostatic
cancer and acute rejection of renal transplant [10]. Very recent
study on diabetic nephropathy novel biomarkers revealed
that exosomal regucalcinwas underexpressed in renal disease
patients [42].
5. Conclusions
Finally we may conclude that urinary EVs have the potential
to be biomarkers of renal damage in diabetic patients, and
the number of structural and enzymatic proteins (including
uromodulin) can be found in urine EVs fraction to be in use
as their indicators or new biomarkers both of renal failure and
of diabetic nephropathy in the future.The easy accessibility of
EVs in urine can increase their use as biomarkers compared
to invasive biopsy. Further validation, characterization of the
content of bioactive molecules, and larger study population
are needed.
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